

# 1 Early diagnosis of transthyretin amyloidosis by detection of monomers in 2 plasma microsamples using a protein crystal-based assay

3

4 Diogo Costa-Rodrigues<sup>a,b,c</sup>, José P. Leite<sup>c</sup>, Maria João Saraiva<sup>a,b</sup>, Maria Rosário Almeida<sup>a,b,c</sup>,  
5 Luís Gales<sup>a,b,c\*</sup>

6

7 <sup>a</sup> i3S – Instituto de Investigação e Inovação em Saúde, Rua Alfredo Allen, 208, Porto, Portugal

8 <sup>b</sup> IBMC – Instituto de Biologia Molecular e Celular, Universidade do Porto, Rua Alfredo Allen, 208, Porto,  
9 Portugal

10 <sup>c</sup> ICBAS – Instituto de Ciências Biomédicas Abel Salazar, Rua de Jorge Viterbo Ferreira 228, Porto, Portugal

11 \* corresponding author: E-mail: [lgales@ibmc.up.pt](mailto:lgales@ibmc.up.pt)

12

## 13 Abstract

14 Amyloid diseases are frequently associated with the appearance of an aberrant form of a  
15 protein, whose detection enables early diagnosis. In the case of transthyretin amyloidosis,  
16 the aberrant protein – the monomers – constitute the smallest species of the amyloid  
17 cascade, which creates engineering opportunities for sensing that remain virtually  
18 unexplored. Here, a two-step assay is devised, combining molecular sieving and  
19 immunodetection, for quantification of circulating monomeric transthyretin in the plasma. It  
20 is shown that mesoporous crystals built from biomolecules can selectively uptake  
21 transthyretin monomers up to measurable quantities. Furthermore, it was found that the use  
22 of endogenous molecules to produce the host framework drastically reduces unspecific  
23 adsorption of plasma proteins at the crystal surface, a feature that was observed with metal-  
24 organic frameworks. The assay was used to analyse plasma microsamples of patients and  
25 healthy controls. It shows a significant increase in the levels of monomeric transthyretin in  
26 the patients, proving its usefulness to establish the monomers as soluble and non-invasive  
27 marker of the disease. In addition, the assay can evaluate transthyretin stabilizers, an  
28 emergent strategy that broadened the treatment approach to the disease. Sensing the initial  
29 event of the transthyretin amyloid cascade with the proposed assay can make the difference  
30 for early diagnosis and eliminate the currently adopted invasive biopsies modalities for  
31 detection of the final products of the aggregation pathway.

32

33 Keywords: amyloid biomarkers; transthyretin monomers; sensors; molecular sieves; protein  
34 crystals; MOFs

## 35 **1. Introduction**

36 Transthyretin related amyloidosis (ATTR) is a highly debilitating and life-threatening  
37 disease. Significant variations in phenotypic and genotypic expression of the disease hamper  
38 early and accurate diagnosis which delays initiation of appropriate treatment (Adams et al.  
39 2016). Current diagnostic methods include tissue biopsy analysis to detect amyloid deposits  
40 and genetic tests to search for TTR mutations. However, the disease can be associated with  
41 deposition of wild-type TTR in the myocardium which cannot be diagnosed by TTR  
42 sequencing.


43 Biopsy tests are focused on the observation of the final products of the amyloid  
44 cascade. Patients carry less stable TTR homotetramers that are prone to dissociation into  
45 non-native monomers, which in turn rapidly self-assemble into oligomers and, ultimately,  
46 amyloid fibrils. New methods for precise monitoring of the initial steps of the amyloid  
47 cascade, i.e. monomeric TTR levels in the plasma, are crucial to evaluate new  
48 pharmacological advances that broadened the treatment approach to ATTR, such as  
49 stabilizers of the native tetrameric TTR structure (Almeida et al. 2005) and antisense  
50 oligonucleotides that inhibit the hepatic production of TTR (Benson et al. 2018; Gales 2019).

51 Here, we devised a mesoporous crystal-based assay for selective extraction of TTR  
52 monomers over the native tetramers for posterior immunodetection (Fig. 1). The crystals  
53 work as sponges that enrich small proteins (including monomeric TTR) from a mixture, up to  
54 measurable quantities. By leveraging the molecular sieving properties of the mesoporous  
55 crystals and reducing unspecific surface adsorption of plasma proteins we developed an  
56 assay for accurate discrimination between the levels of circulating monomeric TTR in ATTR  
57 patients and healthy individuals.

58 Crystals with high density of single sized pores are excellent candidates to separate  
59 mixtures of compounds with similar molecular sizes. Two different types of crystals were  
60 tested: protein crystals and Metal-Organic Frameworks (MOFs). A few researchers have been  
61 calling attention to protein crystals as microporous materials that offer a wide range of pore  
62 size (sometimes exceeding 10 nm), porosity (0.5-0.8), and pore surface area (800-2000 m<sup>2</sup>.g<sup>-1</sup>)  
63 (Vilenchik et al. 1998). Protein crystals are mostly produced to collect X-ray diffraction data  
64 to determine the atomic structure of the constituent molecules. Structural biologists are  
65 often insensible to the remarkable potential of such particles for engineering applications.

66 Despite being soft and fragile solids that quickly dissolve in unfavourable environments,  
67 chemical cross-linking makes protein crystals much more stable, with little change in pore  
68 structure.

69 The most common strategies employed to adjust pore dimensions are size selection of  
70 the host protein and targeting specific network topologies. Several crystalline frameworks  
71 have been constructed with those strategies displaying a large range of pores, from  
72 subnanometer channels achieved by the assembly of short hydrophobic dipeptides (Görbitz  
73 2001) up to proteins that self-assemble into 750 kDa cube-shaped cages with 13 nm inner  
74 cavities (Lai et al. 2014). The crystals have been used as scaffolds to investigate the diffusion  
75 in confined environments of small (Durão and Gales 2013) and large (Cvetkovic et al. 2005)  
76 guest molecules or as hosts to uptake compounds ranging from gas molecules (Afonso et al.  
77 2010; Comotti et al. 2009) to biomacromolecules (Hashimoto et al. 2019). Among the  
78 biomolecules of interest to encapsulate are enzymes (Kowalski et al. 2019) whose stability is  
79 thereby enhanced. Another interesting field is the engineering of self-assembled porous  
80 protein crystals in living cells, aiming applications such as molecular recognition and storage  
81 of exogenous substances (Abe et al. 2017).



82  
83 **Fig. 1.** Schematic representation of the transthyretin amyloid cascade. Tetramer dissociation  
84 is the rate-limiting step. Emergent therapeutic strategies – inhibition of the synthesis of the  
85 protein and stabilization of the native protein – are pointed. Mesoporous materials will be  
86 used here for extracting the monomeric TTR species from plasma samples for subsequent  
87 immunosensing.

88

89           There are not many other crystalline materials that can reach sufficiently wide pores to  
90 encapsulate macromolecules. Another example is the class of MOFs. MOF materials are  
91 being developed for several biomedical applications, such as drug delivery, protection of  
92 biomolecules and cells, phototherapy and sensing (Mendes et al. 2020) . In particular, MOF  
93 sensors perform at least as well as standard methods for many biomarkers (Dong et al. 2020;  
94 Gu et al. 2020; Sheta et al. 2019; Song et al. 2020; Wang et al. 2019; Wu et al. 2020; Zhou et  
95 al. 2018), including several amyloid related agents such as amyloid  $\beta$  peptide,  $\alpha$ -synuclein,  
96 insulin, procalcitonin and prolactin (reviewed in (Leite et al. 2023; Tajahmadi et al. 2023)).  
97 These sensors reduce the overall complexity of currently used protocols, making them more  
98 appealing for a clinical setting. However, there is a focus in Alzheimer’s disease monitoring in  
99 detriment to other amyloidosis that are clearly under studied despite their relevance (e.g.  
100 Parkinson’s disease) or not explored at all (e.g. TTR amyloidosis) (Leite et al. 2023).  
101 Interestingly, in this work MOFs were not used as co-adjuvant materials as in most  
102 applications in construction of amyloid sensors but rather as a molecular sieve for extraction  
103 of the analyte.

104

105

## 106 **2. Experimental Section**

107

### 108 *2.1. Materials*

109           Thermolysin from *Geobacillus stearothermophilus* was purchased from Sigma-Aldrich  
110 (Type X, lyophilized powder, 30-350 units/mg protein (E1%/280)), resuspended as previously  
111 described (Hausrath and Matthews 2002) and used without further purification. Cytochrome  
112 c from bovine heart ( $\geq 95\%$ ) was purchase from Sigma-Aldrich. Terbium nitrate pentahydrate  
113 and 4,4',4''-s-triazine-2,4,6-triyl-tribenzoic acid (H3TATB) were also purchased from Sigma-  
114 Aldrich (UK). All other reagents were of analytical grade.

115

### 116 *2.2. Recombinant human TTR*

117           TTR wild-type (TTR WT) and variants were produced using a bacterial expression  
118 system and purified as previously described (Furuya et al. 1991). Recombinant TTR was

119 dialyzed against endotoxin-free phosphate-buffered saline (PBS), concentrated using Vivaspin  
120 ultrafiltration units (GE Healthcare, Chicago, IL, USA), and quantified using Bradford protein  
121 assay (Bio-Rad, Hercules, CA, USA).

122

### 123 *2.3. Plasma Samples*

124 The utilization of «human blood samples from individuals who requested to perform  
125 blood collection with predictive character at the Center for Predictive and Preventive  
126 Genetics (CGPP) of the IBMC to evaluate the condition of the pre-symptomatic V30M  
127 mutation» was submitted by the group Molecular Neurobiology (i3S) and approved by the  
128 Ethical Committee of the University of Porto (Report n°36/CEUP/2017).

129

### 130 *2.4. Synthesis of Tb-MOF*

131 Tb-MOF was synthesized as described in (Leite et al. 2019) which was adapted with  
132 minor modifications from (Park et al. 2007). Briefly, terbium nitrate ( $1.38 \times 10^{-4}$  mol) and  
133 4,4',4''-s-triazine-2,4,6-triyl-tribenzoic acid ( $4.54 \times 10^{-4}$  mol) were dissolved a mixture of  
134 dimethylacetamide/methanol/water (4.0/0.8/0.2 mL, respectively). The solution was heated  
135 to 378 K for 48 h in a scintillation vial and then slowly cooled to ambient temperature.  
136 Colourless octahedral crystals were clearly visible.

137

### 138 *2.5. Synthesis of cross-linked thermolysin crystals (TLN-CLC)*

139 Tetragonal crystals were grown according to the method described in (Leite and Gales  
140 2019), using the hanging drop vapour diffusion method in 24-well crystallization plates at  
141 20°C. In each well, 500µl of 1M ammonium sulphate was added to the reservoir as  
142 precipitant solution. A drop of 6µl was added to the cover slide; its composition was 50% v/v  
143 of 150 mg·ml<sup>-1</sup> thermolysin dissolved in 45% DMSO, and 50%v/v of 1M zinc chloride also  
144 dissolved in 45% DMSO. After ~24h the presence of crystals was confirmed. Crystallization  
145 conditions were carefully controlled to obtain reproducible crystals. Crystal cross-linking: one  
146 drop of 1µl of 25% v/v glutaraldehyde was added directly to the crystal's drop. The well was  
147 then closed again (well-sealed with grease to avoid vaporization of glutaraldehyde), and the  
148 crystals were left incubating ~1h30min.

149

150 **2.6. Analysis of the monomeric TTR extraction by the mesoporous crystals using SDS-PAGE.**


151 10 mg of MOF crystals were incubated overnight with recombinant TTR at 0.2 mg.ml<sup>-1</sup>  
152 (150 µl sample volume) in PBS 1x, pH 7.4. Crystals were washed to remove superficially  
153 adsorbed protein, dissolved by gentle heating and acidification and resuspended in 50 mM  
154 HEPES pH 7.5. Samples were analysed in 15% (w/v) polyacrylamide gels by SDS-PAGE.  
155 NZYColour Protein Marker II (NZYtech) was used as a molecular weight marker. The same  
156 procedure was used with TLN-CLC but with a sample of five crystals.

157

158 **2.7. Analysis of the monomeric TTR uptake by TLN-CLC using molecular probes cytochrome c**  
159 **and fluorescein**

160 Single TLN-CLC crystals were incubated at RT, for 3 h, in 5 µl drops of TTR (3.6x10<sup>-6</sup> M in  
161 phosphate buffered saline pH 7.4). The void volume of the crystals, which is expected to  
162 diminish by the uptake of TTR monomers, was estimated by two methods, schematically  
163 presented in Fig. 2.

164



165

166 **Fig. 2.** Schemes of the experimental procedure for estimation of the free void volume of the  
167 TLN-CLC crystals after TTR uptake, with fluorescein (A) and cytochrome c (B).

168

169 Method 1 (Fig. 2A): 2 µl of a solution of 1mM fluorescein was added to the crystal drop  
170 and incubated for 2 hours. The crystals were then fish out using a nylon loop, gently placed in  
171 a clean surface to remove the solution in the loop and transferred, also with a loop, to a

172 phosphate buffered saline solution. Fluorescence was measured after 18h (Excitation at 494  
173 nm and emission at 521 nm).

174 Method 2 (Fig. 2B): 10  $\mu$ l of a solution of cytochrome c (5 mg.ml<sup>-1</sup>) was added to the  
175 crystal drop and incubated for 18h. The crystals were fished out with a nylon loop, quickly  
176 passed through a washing solution, and transferred to a reader plate to record a cytochrome  
177 c catalysed colorimetric reaction. Peroxidase activity was determined using 3,5',5,5'-  
178 tetramethylbenzidine (TMB) as described in (Parakra et al. 2018). Briefly, cytochrome c  
179 samples in the presence of TMB (1.6 mM) were reacted with H<sub>2</sub>O<sub>2</sub> (300  $\mu$ M) in phosphate  
180 buffer (pH 5.4, 80 mM), at room temperature. TMB oxidation was follow measuring the  
181 absorbance at 652 nm and the initial velocity of the reaction determined.

182 Three independent experiments were performed for each condition. The morphology  
183 of TLN-CLC crystals was very homogeneous, which was confirmed by optical imaging of the  
184 crystals and by measuring their fluorescein adsorption capacity.

185

#### 186 *2.8. TLN-CLC based assay for evaluation of TTR drug candidates.*

187 Recombinant TTR samples were incubated overnight with tafamidis or acoramidis at  
188 molecular drug/TTR ratios of 10/1, 1/1 and 0/1. Then, the procedure described in section 2.7  
189 was followed. Three independent experiments were performed for each condition.

190

#### 191 *2.9. TLN-CLC based assay for analysis of plasma samples.*

192 Three TLN-CLC crystals were incubated three hours at RT in 5  $\mu$ l drops of plasma  
193 samples. The uptake of TTR monomers, was evaluated by immunoassay analysis, namely  
194 Western Blot and ELISA.

195 Western Blot: After incubation the crystals were fished out using a nylon loop, gently  
196 placed in a clean surface to remove the solution in the loop and transferred, to a PBS  
197 solution. SDS-PAGE analysis was performed (15% (w/v) polyacrylamide gels) and the proteins  
198 transferred onto nitrocellulose membranes. The membranes were blocked with 5% skim milk  
199 in PBS with Tween 20 (PBST), for 1 h at room temperature. Next, the membranes were  
200 incubated overnight at 4 °C, with a rabbit polyclonal antibody against human TTR (DAKO) at a



201 1:500 dilution. The membranes were washed three times in PBST for 5 min and were then  
202 incubated with a secondary antibody, conjugated with HRP (Goat anti-rabbit IgG, at a  
203 1:10000 dilution) for 1 h at room temperature. Protein bands were detected via the  
204 enhanced chemiluminescence technique, using the Clarity ECL detection kit (BIO-RAD). Four  
205 independent experiments were performed for each condition.

206 ELISA: For determination of TTR inside the crystals, rabbit polyclonal anti-human TTR  
207 antibody (DAKO) was used as capture antibody at a 1:500 dilution, sheep anti-human TTR  
208 (Abcam) antibody diluted at 1:2500, as secondary antibody, and lastly was used donkey anti-  
209 sheep antibody (SIGMA) in a dilution of 3:10000. SIGMAFAST (p-nitrophenyl phosphate  
210 tablets) were used and absorbance was determined at 410 nm. Three independent  
211 experiments were performed for each condition.

212

### 213 *2.10. Mass spectrometry (protein gel band, figure 3E).*

214 Peptide cleavage characterization was performed by nanoLC–MS/MS, with a Ultimate  
215 3000 liquid chromatography system coupled to a Q-Exactive Hybrid Quadrupole-Orbitrap  
216 mass spectrometer (Thermo Scientific, Bremen, Germany). Samples were loaded onto a  
217 trapping cartridge in a mobile phase of 2% ACN, 0.1% FA at 10  $\mu\text{L}\cdot\text{min}^{-1}$ . After 3 min loading,  
218 the trap column was switched in-line to a reverse phase column at 300  $\text{nL}\cdot\text{min}^{-1}$ . Separation  
219 was performed with a gradient of 0.1% FA (A) 80% ACN, 0.1% FA (B). The mass spectrometer  
220 was operated in a Full MS positive acquisition mode. The ESI spray voltage was 1.9 kV. The  
221 global settings were use lock masses best ( $m/z$  445.12003), lock mass injection Full MS,  
222 chrom. peak width (FWHM) 30s. The full scan settings were 70k resolution ( $m/z$  200), AGC  
223 target  $3 \times 10^6$ , maximum injection time 200 ms, scan range: 400–4000  $m/z$ .

224

### 225 *2.11. Statistical analysis.*

226 Data was analysed using GraphPad Prism Software (version 9.5.0). Unpaired *t*-test with  
227 Welch's correction was performed. Levels of statistical significance at \*  $p < 0.05$ , \*\*  $p < 0.01$ ,  
228 \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$  were used. The number of independent experiments  
229 performed is given above, in the description of the respective assay.



### 230 3. Results and discussion

231

#### 232 3.1. *Tb-MOF separate TTR monomers from tetramers in vitro but are prone to unspecific* 233 *surface adsorption of plasma proteins*

234 Initial screening for MOFs capable of tailored uptake of TTR monomers and exclusion of  
235 tetramer led us to select Tb-MOF (Fig. 3A), a robust material, stable in several solvents, that  
236 has cages of 3.9 and 4.7 nm (Park et al. 2007). Screening consisted in the incubation of MOF  
237 crystals (10 mg) in samples of pure recombinant TTR variants (0.2 mg.ml<sup>-1</sup>, 150 µl), including  
238 the wild-type protein (TTR-WT) and two highly amyloidogenic variants: TTR-L55P (Bonifácio  
239 et al. 1996) and TTR-Y78F (Redondo et al. 2000). Crystals were then dissolved and analysed  
240 by SDS-PAGE. TTR was detected in all TTR soaking solutions, as expected (Fig. 3B). Crystals  
241 that were pre-incubated with the amyloidogenic variants TTR-L55P and TTR-Y78F  
242 encapsulated measurable quantities of monomeric TTR, while crystals soaked with TTR-WT  
243 did not. The amyloidogenic variants are less stable, more prone to dissociate into monomeric  
244 species that penetrate in the MOF framework.


245 The promising results obtained with pure recombinant TTR solutions prompted us to  
246 investigate the detection of TTR monomers in plasma samples of ATTR patients carrying TTR-  
247 V30M, the most frequent TTR variant associated with amyloidosis worldwide, found  
248 endemically in the northern parts of Sweden, and in regions of Portugal and Japan. We  
249 observed that a mixture of low molecular weight plasma proteins penetrates in the Tb-MOF  
250 framework, which was further separated by gel electrophoresis (Fig. 3C). The gel band with  
251 the expected molecular weight of the TTR monomer was excised and analyzed by mass  
252 spectrometry. TTR-V30M patients are heterozygotes and, accordingly, both the TTR-WT and  
253 the TTR-V30M monomer were identified (Fig. 3D).

254 Unfortunately, inspection of the crystals in contact with plasma samples with a  
255 stereomicroscope reveals the formation of a layer at the surface of the crystals composed by  
256 plasma proteins which may include tetrameric TTR. This external protein layer is hard to  
257 separate from the smaller protein species that occupy the crystal cages. Consequently, SDS  
258 electrophoresis of the dissolved crystals shows high molecular weight protein bands (Fig 3E).  
259 Since it is crucial that the protein extract doesn't become contaminated with tetrameric TTR,  
260 we decided to test other types of mesoporous crystals built with biomolecules – protein

261 cross-linked crystals – with the expectation that they are less prone to surface adsorption of  
262 plasma proteins.

263

264



265  
266 **Fig. 3.** Analysis of the protein extracted from recombinant TTR samples and from plasma  
267 samples by Tb-MOF crystals. **A.** Optical image of Tb-MOF crystals (scale bar 0.5 mm). **B.** SDS  
268 analysis of the dissolved crystals after protein extraction from pure samples of recombinant  
269 TTR. Results shown for the TTR WT and for the amyloidogenic variants TTR-L55P and TTR-  
270 Y78F (Sol. - protein soaking solution and Crystal – protein extracted from the crystals  
271 dissolved after incubation with the soaking solutions). Tb-MOF extracted observable  
272 quantities of protein from the amyloidogenic variants, but not from the TTR WT (mostly  
273 tetrameric). **C.** SDS-PAGE gel of the protein extract from the plasma sample of a TTR-V30M  
274 carrier using Tb-MOF. The band  $\approx$  14kDa (approximate MW of the TTR monomer),  
275 highlighted in the figure, was excised and analysed by mass spectrometry, confirming it as  
276 TTR (**D**). **E.** SDS-PAGE gel of plasma proteins that become adsorbed at the external surface of  
277 Tb-MOF crystals, after 30 min and 1 h of incubation time with TTR-V30M and TTR-WT plasma  
278 samples. Size-excluded proteins become adsorbed which reduces the separation efficiency of  
279 the crystals.

280

281 3.2. *Thermolysin cross-linked crystals (TLN-CLC) separate TTR monomers from tetramers in*  
282 *vitro*


283 TLN crystals grow in two main packing systems, hexagonal and tetragonal. These  
284 distributions can be achieved by modifying one component of the mixing solution: zinc  
285 (Hausrath and Matthews 2002). When grown in media that contain the ion (for example zinc  
286 chloride or zinc acetate), the crystals adopt a tetragonal packing system. In contrast, if the  
287 solution does not contain zinc, the packing will be hexagonal (Leite and Gales 2019).  
288 Tetragonal crystals are more uniform and have a solvent content of 66% (Fig. 4A). Hexagonal  
289 crystals are longer and rod-like and have a solvent content of 46% (Juers et al. 2018). Owing  
290 to the desired application of the crystals, the packing system of greatest interest is the  
291 tetragonal because it displays one-dimensional channels with appropriate dimensions along  
292 the *c*-crystallographic axis. Soakability predictions of crystal channels using *MAP\_CHANNELS*  
293 (Juers and Ruffin 2014) and *LifeSoaks* (Pletzer-Zelgert et al. 2023) provided an overall  
294 bottleneck radius of 1.7 nm and a maximum pore radius of 2.0 nm. The surface of the TLN  
295 crystal channels show an overall hydrophobic environment and display only weak and  
296 localised charges. The target protein, TTR, in the native tetrameric form has a maximum  
297 dimension of 7.0 nm. Despite the lack of information about the structure and flexibility of  
298 monomeric TTR, the channel dimensions make tetragonal TLN crystals good candidates for  
299 extraction of the TTR monomeric species and size-exclusion of the tetramers (Fig. 4B).  
300 Furthermore, it is known that TTR dissociation exposes hydrophobic regions in the monomer  
301 surface (Kim et al. 2016) which probably drives diffusion from the bulk solution and  
302 potentiate pore entrapment; accordingly, the low charged surface of TLN channels generate  
303 an amenable chemical environment for uptake of TTR monomers.

304 The packing of the grown crystals was confirmed by single crystal X-ray diffraction using  
305 an in-house equipment (Rigaku/Oxford Diffraction Gemini PX Ultra single-crystal X-ray  
306 diffractometer). Crystals were then cross-linked with glutaraldehyde, incubated with five  
307 recombinant TTR variants and then the protein uptake from each sample was analysed. The  
308 five TTR variants tested were three amyloidogenic mutants, TTR-Y78F, TTR-L55P and TTR-  
309 V30M, the TTR-WT and one variant with protective effect TTR-T119M (Almeida et al. 2000).  
310 Western blotting analysis using an antibody targeting human TTR shows that TTR uptake is  
311 higher for TTR-Y78F, TTR-L55P and TTR-V30M than for TTR-WT and TTR-T119M, and thus  
312 that it correlates with TTR quaternary instability (Fig 4C). The fact that TTR-T119M which is

313 even more stable than TTR-WT is hardly detected gives a clear indication that the native TTR  
314 tetramer does not penetrate in the TLN-CLC framework.

315 In addition, we developed a cheaper alternative strategy to the use of anti-TTR  
316 antibodies to access the crystal extraction from pure recombinant TTR samples. Uptake of  
317 TTR monomers reduces the empty porous volume of the crystal that will be subsequently  
318 occupied by a secondary guest prone to optical sensing. Two secondary guests were tested.  
319 One is cytochrome c that has similar molecular dimensions to the TTR monomer and was  
320 already shown to almost fulfil the accessible void volume of MOF mesoporous crystals (Chen  
321 et al. 2012). If the same trend is observed with TLN-CLC crystals - almost complete occupation  
322 of the free void volume – it provides an indirect method to quantify monomeric TTR  
323 extraction. Cytochrome c catalyses a colorimetric reaction, and the initial velocity of the  
324 reaction catalysed by the crystals was used to access the crystal incorporation of this  
325 enzyme. The other probe tested is fluorescein, that should diffuse freely through the large  
326 pores of the TLN-CLC framework and equilibrate with the bulk solution concentration.  
327 Fluorescence intensity of this compound enables facile quantification of the uptake extent.  
328 The results of the assays that make use of the secondary probes are presented in Fig. 4 D and  
329 E. The secondary probes are inverted indicators of the monomeric TTR uptake: crystals pre-  
330 incubated with the amyloidogenic variants show lower uptake of the secondary probe (due  
331 to the occupation of the crystal void volume by monomeric TTR) when compared with the  
332 ones incubated with the stable TTR variants, which agrees with the western blot analysis  
333 (figure 3A). The assay is thus useful for facile and cheap sensing of monomers present in pure  
334 recombinant TTR samples. The results with the two secondary probes show a similar trend;  
335 there are not significant variations in the extraction of the three amyloidogenic variants  
336 tested. Extraction of TTR-T119M monomers looks slightly lower than the TTR-WT, as  
337 expected, due to the quaternary stabilizing role of this mutation.

338



339  
 340 **Fig. 4.** TLN-CLC efficiently extract TTR monomer from amyloidogenic TTR samples up to  
 341 observable quantities. **A.** Optical image of TLN-CLC (scale bar 0.5 mm). **B.** Crystal structures  
 342 of TTR with one of the monomers highlighted in green (PDB 1Y1D (Gales et al. 2005)) and of  
 343 the TLN tetragonal framework (PDB 6N4Z (Harrison et al. 2019)). **C.** Western blotting analysis,  
 344 with an antibody targeting human TTR, of the uptake by TLN-CLC crystals of TTR variants  
 345 displaying a range of quaternary stability behaviours. **D** and **E.** Correlation between the  
 346 crystal free void volumes after incubation with several TTR variants, estimated with  
 347 fluorescein and cytochrome c, respectively. **F.** A colorimetric reaction was used to estimate  
 348 cytochrome c trapped in the crystals (considered to be proportional to the reaction initial  
 349 velocities). Examples of reaction progression curves used to estimate initial velocities are  
 350 shown (color code of TTR variants in which the crystals were pre-incubated as in **E.** Three  
 351 independent experiments were performed for each condition.

352

353

### 354 3.3. TLN-CLC-based assay enables the evaluation the TTR drug candidates at nearly 355 physiologic conditions.


356 Small compounds, mostly binding in the TTR channel, are being developed to stabilize  
 357 the protein native structure and therefore inhibit TTR amyloid formation. This therapeutic  
 358 strategy is being persecuted for many years and, as a result, tafamidis became the first

359 compound approved for the treatment of TTR amyloidosis by the European Commission and  
360 the FDA. Here, we evaluated the protective effect of two TTR stabilizers, Tafamidis and  
361 Acoramidis, at nearly physiologic conditions.

362 Tafamidis, or 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid, selectively binds  
363 TTR and kinetically stabilizes WT-TTR and mutant tetramers under denaturing and  
364 physiologic conditions, inhibiting amyloidogenesis (Bulawa et al. 2012). The authors  
365 overcame the difficulty to detect monomeric species under physiologic conditions indirectly,  
366 using subunit exchange experiments. A double-blind clinical trial demonstrated the efficacy  
367 of tafamidis in slowing the progression of TTR (Coelho et al. 2012). Acoramidis (AG10), or 3-  
368 [3-(3,5-dimethyl-1h-pyrazol-4-yl)propoxy]-4-fluorobenzoic acid, is another promising drug  
369 that achieves near-complete stabilization of TTR in the plasma (Judge et al. 2019). It is  
370 currently in clinical trials for the treatment of TTR Amyloidosis (Fox et al. 2020).

371 The amyloidogenic proteins variants TTR-L55P and TTR-Y78F were used, and  
372 experiments were performed with drug / TTR molar ratios of 10/1, 1/1 and 0/1. The results  
373 are presented in Fig. 5. The two molecular probes (cytochrome c and fluorescein) used to  
374 estimate crystal void volumes yielded similar results (no statistically significant differences  
375 observed). In general, there was a significant reduction in the dissociation into monomers  
376 after addition of equimolar concentration of the drug; increasing 10x the concentration of  
377 the drug further increases the stability of the tetramer at physiological conditions. A drug /  
378 TTR molar ratio of 10/1, but not of 1/1, yielded dissociation rates equivalent to the TTR-WT.  
379 The assay is not sensible enough to detect significant differences between the action of  
380 tafamidis and acoramidis. Also, a consistent drug stabilizing effect was observed towards the  
381 two amyloidogenic variants.

382



383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

**Fig. 5.** Application of TLN-CLC-based assay for evaluation of TTR stabilizers at nearly physiological conditions. Two drugs were tested, tafamidis (top) and acoramidis (bottom), with the amyloidogenic variants TTR-L55P and TTR-Y78F. Drug / TTR molar ratio: 10 /1, 1/1 and 0/1. TTR monomer uptake estimated indirectly, using secondary probes cytochrome c and fluorescein. Stability of the TTR variants is very sensitive do the drug / protein stoichiometry; the two drugs show a similar activity with both TTR variants. Results from three independent experiments for each condition.

Thus, we devised an in vitro assay for facile evaluation of the effect of compounds on TTR stability at physiologic pH. The assay outcomes the technical complexity of other indirect methods already in use, such as the determination of TTR subunit exchange rates (Nelson et al. 2021). Moreover, the assay is very sensitive to the drug / protein stoichiometry. It also reveals that stabilizing effect of the two compounds tested, tafamidis and acoramidis, in the amyloidogenic variants TTR-L55P and TTR-Y78F is very similar.



400 *3.4. TLN-CLC - based assay reveals increased levels of TTR monomers in the plasma of TTR*  
401 *amyloidosis patients.*

402 Sensing monomeric TTR in plasma microsamples and proving the utility of the assay to  
403 discriminate between carriers of amyloidogenic TTR variants and TTR-WT constitute the main  
404 goal of this work. The TLN-CLC - based assay was tested with plasma samples of ten  
405 individuals, five carriers of TTR-V30M (# 53, 55, 56, 61 and 69) and five healthy controls (#  
406 51, 52, 54, 57 and 58).


407 TLN-CLC crystals were incubated in 5  $\mu$ l plasma samples for 3 h and the protein uptake  
408 analysed. We first checked by SDS analysis that unspecific adsorption of high molecular  
409 weight plasma proteins in the external surface of TLN-CLC crystals was negligible (not  
410 shown), providing a critical advantage towards the use of Tb-MOF crystals. This is crucial  
411 because the immunosensing assay that will be used subsequently for quantification of TTR  
412 collected from the crystals, does not efficiently discriminate between tetramers and  
413 monomers.

414 Identification of the target protein in the crystals' extracts was accomplished by anti-  
415 TTR Western blotting (Fig. 6A). Despite the variations observed in the monomeric TTR gel  
416 band intensities among the samples of TTR-V30M carriers, imaging analysis shows that they  
417 are significantly stronger than the ones of the controls. It should be noticed that semi-  
418 denaturing conditions were used, which enables the detection of the dimeric TTR band when  
419 a solution of TTR-WT is loaded (positive control). The TTR dimer is not detected in the crystal  
420 extracts which confirms that TTR surface adsorption is negligible.

421 The monomeric TTR released from the TLN-CLC crystals, after incubation in plasma  
422 samples, was analysed by ELISA (Fig, 6B). In addition, the ELISA assay was also used to  
423 quantify the total concentration of TTR in plasma samples. It was observed that plasma TTR  
424 concentration of the TTR-V30M carriers is lower than the one of healthy controls, a feature  
425 already pointed for carriers of other amyloidogenic mutations such as TTR-V122I (Buxbaum  
426 et al. 2008). Moreover, it was also already noticed that age, gender and progression of the  
427 disease influence in a statistically significant manner the serum TTR levels (Buxbaum et al.  
428 2008), which, together with the small sample size used here, may contribute to  
429 heterogeneity of the results. To exclude the effect of the variations in the levels of total

430 plasma TTR, we found more reliable to use the monomeric TTR / total TTR ratio instead of  
431 the monomeric TTR alone.

432



433

434 **Fig. 6.** TLN-CLC - based assay reveals increased levels of TTR monomers in the plasma of TTR-  
435 V30M carriers. A. Representative anti-TTR Western blots of protein extracted by TLN-CLC  
436 crystals from plasma samples of TTR-V30M carriers (n= 5, +, red) and healthy individuals  
437 (n=5, -, green). Negative control: TLN-CLC crystal; Positive control: recombinant TTR-WT  
438 sample. Inset: Comparison between TTR band intensity between carriers and non-carriers of  
439 TTR-V30M determined by image analysis of the protein bands (four independent  
440 experiments for each plasma sample, 40 protein bands in total). B. Ratio of monomeric  
441 (extracted by the TLN-CLC)/ total TTR in plasma samples, quantified by ELISA. Inset:  
442 Comparison between the two groups of individuals, TTR-V30M carriers (red) and non-  
443 carriers (green). Three independent experiments were performed for each condition.

444

445 The monomeric TTR / total TTR ratio was determined for the plasma samples of the 10  
446 individuals (three independent experiments for each sample) and the results are presented  
447 in Fig. 6B. TLN-CLC crystals extract a fraction of  $10^{-4}$  to  $10^{-3}$  of the total TTR in the plasma  
448 samples. Comparison between the two groups of individuals, shows that the monomeric TTR  
449 / total TTR ratio of the TTR-V30M carriers is higher than normal in a statistically significant  
450 manner. As expected, the difference towards the control group is bigger than the obtained by  
451 anti-TTR Western blotting of the monomers (insets of Fig. 6A and B) due to the normalization  
452 by the respective plasma concentration of total TTR. In line with our results, the presence of  
453 TTR oligomers circulating in the plasma of patients that are carriers of TTR-V30M in  
454 concentrations above healthy controls was already detected using peptide probes (Schonhoft  
455 et al. 2017). According to the established TTR amyloid cascade, the oligomers are formed by  
456 the self-assembly of monomers, not of native tetramers.

457 It is interesting to notice that no statistically significant variations were observed within  
458 the control group, an indication that the monomeric TTR / total TTR ratio eliminates gender  
459 and age caused variations, becoming a reliable indicator of disease progression. On the other  
460 hand, variations among the group of individuals carrying the TTR-V30M are much more  
461 pronounced, probably due to different stages in the disease progression within the group, a  
462 feature that could not be confirmed because the clinical state of the individuals carrying the  
463 amyloidogenic mutation was not disclosed.

464

465

#### 466 **4. Conclusion**

467 Tetramer dissociation is the controlling step in TTR amyloidogenesis which prompted us  
468 to develop an assay to detect variations in the concentration of circulating monomeric TTR.  
469 The assay is technically simple to apply, demands a small volume of plasma sample (around 5  
470  $\mu$ l) and aims to sense a more suitable target (monomeric TTR) for early diagnosis and  
471 accurate evaluation of any therapeutic intervention than standard techniques, which analyse  
472 the deposition of amyloid aggregates. Moreover, the use of a fluid biomarker (circulating  
473 monomeric TTR) eliminates the currently adopted invasive biopsies modalities.

474           The assay was tested with two groups of five individuals each, one composed by  
475 carriers of TTR-V30M variant and the other by healthy controls. It was observed that TTR  
476 amyloidosis patients have significantly higher concentration of monomeric TTR than healthy  
477 controls. Moreover, determination of monomeric TTR / total TTR ratio was found to be more  
478 reliable than that of monomeric TTR alone. This is because total TTR concentration varies  
479 from individual to individual due to several factors, such as gender, age and the progression  
480 of the disease itself. The same is found in diagnostic of the Alzheimer's disease, in which the  
481 concentration of the more aggressive amyloid beta peptide 1-42 in the cerebrospinal fluid  
482 (CSF) is normalized by the basal production of amyloid beta peptide 1-40, that varies  
483 between individuals (Gales 2024).

484           Typical immunosensing assays rely on surface-capture of target molecules, but this  
485 constraint limits specificity towards the monomeric over the tetrameric TTR. We thus used  
486 instead mesoporous crystalline materials, which usually display excellent molecular sieving  
487 properties. While performing experiments with different materials we found much more  
488 challenging to work with plasma samples than with pure recombinant TTR samples, due to  
489 unspecific adsorption of plasma proteins to the external surface of the crystalline particles. In  
490 our test conditions, surface adsorption was much more severe in case of hybrid metal-  
491 organic materials than with protein-based materials. The later enabled us to develop the  
492 proposed assay. Implementation of the assay is facilitated by the availability from commercial  
493 sources of the protein selected to construct the porous framework, thermolysin, and by the  
494 ease to grow the crystals abundantly.

495           Quantification of monomeric TTR concentrations can be useful not only for aiding  
496 physicians in point-of-care diagnosis but also for following the response to emergent  
497 therapies focused on the administration of TTR stabilizers. In this context, circulating  
498 monomeric TTR should be the ideal response-to-treatment biomarker. Finally, we have also  
499 developed an optical assay that can be used to evaluate TTR drug candidates in vitro under  
500 nearly physiological conditions. This is an improvement towards standard methods that use  
501 critical experimental conditions, such as low pH, and to other demanding methods used to  
502 assess the residual monomeric TTR levels observed at physiological pH.

503

504

505

## 506 **Acknowledgements**

507 This work was supported by National funds through FCT—Fundação para a Ciência e a  
508 Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior in the framework of the  
509 projects “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-  
510 007274) and by European Union's Horizon 2020 research and innovation programme under  
511 grant agreement No. 952334 (PhasAGE).

512 FCT is gratefully acknowledged for the PhD grant SFRH/BD/151016/2021 (to D.C.).  
513 Protein production and purification performed at the i3S Biochemical and Biophysical  
514 Technologies Platform. The mass spectrometry analysis done at the Proteomics i3S Scientific  
515 Platform with the assistance of Hugo Osório and the support of the Portuguese Mass  
516 Spectrometry Network (ROTEIRO/0028/2013; LISBOA-01-0145-FEDER-022125).

517

518

## 519 **References**

- 520 Abe, S., Tabe, H., Ijiri, H., Yamashita, K., Hirata, K., Atsumi, K., Shimoi, T., Akai, M., Mori, H., Kitagawa,  
521 S., Ueno, T., 2017. Crystal Engineering of Self-Assembled Porous Protein Materials in Living Cells. *ACS*  
522 *Nano* 11(3), 2410-2419.
- 523 Adams, D., Suhr, O.B., Hund, E., Obici, L., Tournev, I., Campistol, J.M., Slama, M.S., Hazenberg, B.P.,  
524 Coelho, T., 2016. First European consensus for diagnosis, management, and treatment of  
525 transthyretin familial amyloid polyneuropathy. *Curr Opin Neurol* 29 Suppl 1(Suppl 1), S14-26.
- 526 Afonso, R.V., Durão, J., Mendes, A., Damas, A.M., Gales, L., 2010. Dipeptide crystals as excellent  
527 permselective materials: Sequential exclusion of argon, nitrogen, and oxygen. *Angewandte Chemie -*  
528 *International Edition* 49(17), 3034-3036.
- 529 Almeida, M.R., Alves, I.L., Terazaki, H., Ando, Y., Saraiva, M.J., 2000. Comparative studies of two  
530 transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and  
531 TTR T119M. *Biochem Biophys Res Commun* 270(3), 1024-1028.
- 532 Almeida, M.R., Gales, L., Damas, A.M., Cardoso, I., Saraiva, M.J., 2005. Small transthyretin (TTR)  
533 ligands as possible therapeutic agents in TTR amyloidoses. *Curr Drug Targets CNS Neurol Disord* 4(5),  
534 587-596.
- 535 Benson, M.D., Waddington-Cruz, M., Berk, J.L., Polydefkis, M., Dyck, P.J., Wang, A.K., Planté-  
536 Bordeneuve, V., Barroso, F.A., Merlini, G., Obici, L., Scheinberg, M., Brannagan, T.H., Litchy, W.J.,  
537 Whelan, C., Drachman, B.M., Adams, D., Heitner, S.B., Conceição, I., Schmidt, H.H., Vita, G., Campistol,  
538 J.M., Gamez, J., Gorevic, P.D., Gane, E., Shah, A.M., Solomon, S.D., Monia, B.P., Hughes, S.G., Jesse  
539 Kwoh, T., McEvoy, B.W., Jung, S.W., Baker, B.F., Ackermann, E.J., Gertz, M.A., Coelho, T., 2018.  
540 Inotersen treatment for patients with Hereditary transthyretin amyloidosis. *New England Journal of*  
541 *Medicine* 379(1), 22-31.

- 542 Bonifácio, M.J., Sakaki, Y., Saraiva, M.J., 1996. 'In vitro' amyloid fibril formation from transthyretin:  
543 The influence of ions and the amyloidogenicity of TTR variants. *Biochimica et Biophysica Acta -*  
544 *Molecular Basis of Disease* 1316(1), 35-42.
- 545 Bulawa, C.E., Connelly, S., DeVit, M., Wang, L., Weigel, C., Fleming, J.A., Packman, J., Powers, E.T.,  
546 Wiseman, R.L., Foss, T.R., Wilson, I.A., Kelly, J.W., Labaudinière, R., 2012. Tafamidis, a potent and  
547 selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. *Proceedings of the National*  
548 *Academy of Sciences of the United States of America* 109(24), 9629-9634.
- 549 Buxbaum, J., Koziol, J., Connors, L.H., 2008. Serum transthyretin levels in senile systemic amyloidosis:  
550 effects of age, gender and ethnicity. *Amyloid* 15(4), 255-261.
- 551 Chen, Y., Lykourinou, V., Vetromile, C., Hoang, T., Ming, L.J., Larsen, R.W., Ma, S., 2012. How can  
552 proteins enter the interior of a MOF? investigation of cytochrome c translocation into a MOF  
553 consisting of mesoporous cages with microporous windows. *Journal of the American Chemical*  
554 *Society* 134(32), 13188-13191.
- 555 Coelho, T., Maia, L.F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P.,  
556 Suhr, O.B., Campistol, J.M., Conceição, I.M., Schmidt, H.H., Trigo, P., Kelly, J.W., Labaudinière, R., Chan,  
557 J., Packman, J., Wilson, A., Grogan, D.R., 2012. Tafamidis for transthyretin familial amyloid  
558 polyneuropathy: a randomized, controlled trial. *Neurology* 79(8), 785-792.
- 559 Comotti, A., Bracco, S., Distefano, G., Sozzani, P., 2009. Methane, carbon dioxide and hydrogen  
560 storage in nanoporous dipeptide-based materials. *Chemical Communications*(3), 284-286.
- 561 Cvetkovic, A., Picioareanu, C., Straathof, A.J.J., Krishna, R., Van Der Wielen, L.A.M., 2005. Relation  
562 between pore sizes of protein crystals and anisotropic solute diffusivities. *Journal of the American*  
563 *Chemical Society* 127(3), 875-879.
- 564 Dong, X., Zhao, G., Li, X., Fang, J., Miao, J., Wei, Q., Cao, W., 2020. Electrochemiluminescence  
565 immunosensor of "signal-off" for beta-amyloid detection based on dual metal-organic frameworks.  
566 *Talanta* 208, 120376.
- 567 Durão, J., Gales, L., 2013. Guest diffusion in dipeptide crystals. *CrystEngComm* 15(8), 1532-1535.
- 568 Fox, J.C., Hellawell, J.L., Rao, S., O'Reilly, T., Lumpkin, R., Jernelius, J., Gretler, D., Sinha, U., 2020. First-  
569 in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the  
570 Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and  
571 Pharmacodynamic Study in Healthy Adult Volunteers. *Clinical Pharmacology in Drug Development*  
572 9(1), 115-129.
- 573 Furuya, H., Saraiva, M.J.M., Gawinowicz, M.A., Alves, I.L., Costa, P.P., Sasaki, H., Goto, I., Sakaki, Y.,  
574 1991. Production of recombinant human transthyretin with biological activities toward the  
575 understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP). *Biochemistry*  
576 30(9), 2415-2421.
- 577 Gales, L., 2019. Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of  
578 Adult Patients with Hereditary Transthyretin Amyloidosis. *Pharmaceuticals (Basel)* 12(2).
- 579 Gales, L., 2024. Detection and clearance in Alzheimer's disease: leading with illusive chemical,  
580 structural and morphological features of the targets. *Neural Regeneration Research* 19(3), 497-498.
- 581 Gales, L., Macedo-Ribeiro, S., Arsequell, G., Valencia, G., Saraiva, M.J., Damas, A.M., 2005. Human  
582 transthyretin in complex with iododiflunisal: Structural features associated with a potent amyloid  
583 inhibitor. *Biochemical Journal* 388(2), 615-621.

- 584 Görbitz, C.H., 2001. Nanotube formation by hydrophobic dipeptides. *Chemistry - A European Journal*  
585 7(23), 5153-5159.
- 586 Gu, C., Liu, Y., Hu, B., Liu, Y., Zhou, N., Xia, L., Zhang, Z., 2020. Multicomponent nanohybrids of  
587 nickel/ferric oxides and nickel cobaltate spinel derived from the MOF-on-MOF nanostructure as  
588 efficient scaffolds for sensitively determining insulin. *Anal. Chim. Acta* 1110, 44-55.
- 589 Harrison, K., Wu, Z., Juers, D.H., 2019. A comparison of gas stream cooling and plunge cooling of  
590 macromolecular crystals. *Journal of Applied Crystallography* 52(5), 1222-1232.
- 591 Hashimoto, T., Ye, Y., Matsuno, A., Ohnishi, Y., Kitamura, A., Kinjo, M., Abe, S., Ueno, T., Yao, M.,  
592 Ogawa, T., Matsui, T., Tanaka, Y., 2019. Encapsulation of biomacromolecules by soaking and co-  
593 crystallization into porous protein crystals of hemocyanin. *Biochemical and Biophysical Research*  
594 *Communications* 509(2), 577-584.
- 595 Hausrath, A.C., Matthews, B.W., 2002. Thermolysin in the absence of substrate has an open  
596 conformation. *Acta Crystallographica Section D* 58(6 Part 2), 1002-1007.
- 597 Judge, D.P., Heitner, S.B., Falk, R.H., Maurer, M.S., Shah, S.J., Witteles, R.M., Grogan, M., Selby, V.N.,  
598 Jacoby, D., Hanna, M., Nativi-Nicolau, J., Patel, J., Rao, S., Sinha, U., Turtle, C.W., Fox, J.C., 2019.  
599 Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. *Journal of*  
600 *the American College of Cardiology* 74(3), 285-295.
- 601 Juers, D.H., Farley, C.A., Saxby, C.P., Cotter, R.A., Cahn, J.K.B., Holton-Burke, R.C., Harrison, K., Wu, Z.,  
602 2018. The impact of cryosolution thermal contraction on proteins and protein crystals: volumes,  
603 conformation and order. *Acta Crystallographica Section D* 74(9), 922-938.
- 604 Juers, D.H., Ruffin, J., 2014. MAP-CHANNELS: A computation tool to aid in the visualization and  
605 characterization of solvent channels in macromolecular crystals. *Journal of Applied Crystallography*  
606 47(6), 2105-2108.
- 607 Kim, J.H., Oroz, J., Zweckstetter, M., 2016. Structure of Monomeric Transthyretin Carrying the  
608 Clinically Important T119M Mutation. *Angewandte Chemie International Edition* 55(52), 16168-  
609 16171.
- 610 Kowalski, A.E., Johnson, L.B., Dierl, H.K., Park, S., Huber, T.R., Snow, C.D., 2019. Porous protein crystals  
611 as scaffolds for enzyme immobilization. *Biomaterials Science* 7(5), 1898-1904.
- 612 Lai, Y.T., Reading, E., Hura, G.L., Tsai, K.L., Laganowsky, A., Asturias, F.J., Tainer, J.A., Robinson, C.V.,  
613 Yeates, T.O., 2014. Structure of a designed protein cage that self-assembles into a highly porous cube.  
614 *Nat Chem* 6(12), 1065-1071.
- 615 Leite, J.P., Figueira, F., Mendes, R.F., Almeida Paz, F.A., Gales, L., 2023. Metal–Organic Frameworks as  
616 Sensors for Human Amyloid Diseases. *ACS Sensors* 8(3), 1033-1053.
- 617 Leite, J.P., Gales, L., 2019. Alzheimer's A $\beta$ 1-40 peptide degradation by thermolysin: evidence of  
618 inhibition by a C-terminal A $\beta$  product. *FEBS Letters* 593(1), 128-137.
- 619 Leite, J.P., Rodrigues, D., Ferreira, S., Figueira, F., Almeida Paz, F.A., Gales, L., 2019. Mesoporous  
620 Metal–Organic Frameworks as Effective Nucleating Agents in Protein Crystallography. *Crystal Growth*  
621 *& Design* 19(3), 1610-1615.
- 622 Mendes, R.F., Figueira, F., Leite, J.P., Gales, L., Almeida Paz, F.A., 2020. Metal-organic frameworks: a  
623 future toolbox for biomedicine? *Chem Soc Rev* 49(24), 9121-9153.
- 624 Nelson, L.T., Paxman, R.J., Xu, J., Webb, B., Powers, E.T., Kelly, J.W., 2021. Blinded potency comparison  
625 of transthyretin kinetic stabilisers by subunit exchange in human plasma. *Amyloid* 28(1), 24-29.



- 626 Parakra, R.D., Kleffmann, T., Jameson, G.N.L., Ledgerwood, E.C., 2018. The proportion of Met80-  
627 sulfoxide dictates peroxidase activity of human cytochrome c. *Dalton Transactions* 47(27), 9128-9135.
- 628 Park, Y.K., Sang, B.C., Kim, H., Kim, K., Won, B.H., Choi, K., Choi, J.S., Ahn, W.S., Won, N., Kim, S., Dong,  
629 H.J., Choi, S.H., Kim, G.H., Cha, S.S., Young, H.J., Jin, K.Y., Kim, J., 2007. Crystal structure and guest  
630 uptake of a mesoporous metal-organic framework containing cages of 3.9 and 4.7 nm in diameter.  
631 *Angewandte Chemie - International Edition* 46(43), 8230-8233.
- 632 Pletzer-Zelgert, J., Ehrhart, C., Fender, I., Griewel, A., Flachsenberg, F., Klebe, G., Rarey, M., 2023.  
633 LifeSoaks: A tool for analyzing solvent channels in protein crystals and obstacles for soaking  
634 experiments. *Acta Crystallographica Section D: Structural Biology* 79, 837-856.
- 635 Redondo, C., Damas, A.M., Olofsson, A., Lundgren, E., Saraiva, M.J.M., 2000. Search for intermediate  
636 structures in transthyretin fibrillogenesis: Soluble tetrameric Tyr78Phe TTR expresses a specific  
637 epitope present only in amyloid fibrils. *Journal of Molecular Biology* 304(3), 461-470.
- 638 Schonhoft, J.D., Monteiro, C., Plate, L., Eisele, Y.S., Kelly, J.M., Boland, D., Parker, C.G., Cravatt, B.F.,  
639 Teruya, S., Helmke, S., Maurer, M., Berk, J., Sekijima, Y., Novais, M., Coelho, T., Powers, E.T., Kelly, J.W.,  
640 2017. Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis  
641 patients. *Science Translational Medicine* 9(407).
- 642 Sheta, S.M., El-Sheikh, S.M., Abd-Elzaher, M.M., 2019. A novel optical approach for determination of  
643 prolactin based on Pr-MOF nanofibers. *Anal. Bioanal. Chem.* 411(7), 1339-1349.
- 644 Song, X., Shao, X., Dai, L., Fan, D., Ren, X., Sun, X., Luo, C., Wei, Q., 2020. Triple Amplification of  
645 3,4,9,10-Perylenetetracarboxylic Acid by Co(2+)-Based Metal-Organic Frameworks and Silver-Cysteine  
646 and Its Potential Application for Ultrasensitive Assay of Procalcitonin. *ACS Appl. Mater. Interfaces*  
647 12(8), 9098-9106.
- 648 Tajahmadi, S., Molavi, H., Ahmadijokani, F., Shamloo, A., Shojaei, A., Sharifzadeh, M., Rezakazemi, M.,  
649 Fatehizadeh, A., Aminabhavi, T.M., Arjmand, M., 2023. Metal-organic frameworks: A promising option  
650 for the diagnosis and treatment of Alzheimer's disease. *Journal of Controlled Release* 353, 1-29.
- 651 Vilenchik, L.Z., Griffith, J.P., St. Clair, N., Navia, M.A., Margolin, A.L., 1998. Protein Crystals as Novel  
652 Microporous Materials. *Journal of the American Chemical Society* 120(18), 4290-4294.
- 653 Wang, Z., Hu, X., Sun, N., Deng, C., 2019. Aptamer-functionalized magnetic metal organic framework  
654 as nanoprobe for biomarkers in human serum. *Anal. Chim. Acta* 1087, 69-75.
- 655 Wu, Q., Tan, R., Mi, X., Tu, Y., 2020. Electrochemiluminescent aptamer-sensor for alpha synuclein  
656 oligomer based on a metal-organic framework. *Analyst* 145(6), 2159-2167.
- 657 Zhou, Y., Li, C., Li, X., Zhu, X., Ye, B., Xu, M., 2018. A sensitive aptasensor for the detection of  $\beta$ -  
658 amyloid oligomers based on metal-organic frameworks as electrochemical signal probes. *Anal.*  
659 *Methods* 10(36), 4430-4437.
- 660